Nexyra Journal
Structured evidence dossiers on research compounds — clinical trial summaries, mechanism overviews, primary-source citations, and honest evidence-level grading. Each dossier is a reference document, not marketing copy.
All content is for research planning purposes only. Not medical advice. All Nexyra Lab products are for research use and not for human or veterinary use.
Retatrutide — Research Dossier
A structured evidence dossier on Retatrutide (LY3437943), a triple GIP/GLP-1/glucagon receptor agonist. Phase 2 NEJM 2023 data, Phase 3 TRIUMPH toplines (TRIUMPH-1 and TRIUMPH-4), safety profile, regulatory status, and full primary-source references.
Mechanism
Triple agonist
Phase 2 peak result
24.2%
Phase 3 peak result
30.3%
Tesamorelin — Research Dossier
A structured evidence dossier on Tesamorelin (Egrifta), the only FDA-approved GHRH analogue in the Nexyra catalogue. Phase 3 pivotal trial results (15–18% visceral fat reduction), off-label liver research, safety profile, and regulatory status.
Mechanism
GHRH analogue
FDA approval
2010
Visceral fat reduction
15–18%
BPC-157 — Research Dossier
A structured evidence dossier on BPC-157. 35 of 36 studies in a 2025 systematic review are preclinical; zero controlled human trials recorded. Mechanistic pathways, limitations of the rodent literature, and regulatory status.
Studies reviewed
36
Preclinical studies
35
Controlled human trials
0
CJC-1295 — Research Dossier
A structured evidence dossier on CJC-1295. The 2006 Teichman Phase 1/2 trial in healthy adults showed 2–10× sustained GH elevation over 6+ days (DAC form). The widely sold "no-DAC" product is a different molecule. Development did not advance beyond early trials.
Key study
2006
GH increase (DAC)
2–10×
IGF-1 increase (DAC)
1.5–3×
HCG — Research Dossier
A structured evidence dossier on HCG (human chorionic gonadotropin). FDA-approved for fertility and endocrine indications. The weight-loss claim is unsupported: a 24-study meta-analysis found no evidence of benefit; the FDA label states it is not effective for obesity. OTC HCG weight-loss products were declared fraudulent in 2011.
FDA status
Approved
Weight-loss evidence
None
OTC HCG products
Banned 2011
HGH — Research Dossier
A structured evidence dossier on recombinant human growth hormone (somatropin). FDA-approved for defined deficiency states; controlled trials in healthy elderly show modest body-composition change with significant adverse effects — risks outweigh benefits.
Structure
191 aa
FDA status
Approved
Anti-ageing use
Not approved
Ipamorelin — Research Dossier
A structured evidence dossier on Ipamorelin. Two human PK/PD studies; one discontinued Phase 2 (postoperative ileus). Selectively stimulates GH without raising cortisol, prolactin, or ACTH — a pharmacological distinction established mainly in preclinical models. No approvals.
First described
1998
Human PK/PD studies
2
Phase 2 trials
1
NAD⁺ — Research Dossier
A structured evidence dossier on NAD⁺. Age-related decline is well documented. Most human RCT evidence tests oral precursors (NR/NMN) and surrogate endpoints — NAD⁺ levels, not hard clinical outcomes. Direct evidence for injectable NAD⁺ is limited.
Age-related decline
Multi-tissue
Precursor effect (NR/NMN)
~2×
Human endpoints
Surrogate-led
TB-500 — Research Dossier
A structured evidence dossier on TB-500 (thymosin beta-4). Phase 2–3 human trials exist in ophthalmic and dermal indications; zero completed trials for systemic musculoskeletal use. Evidence base, naming distinction from thymosin alpha-1, and regulatory status.
First isolated
1960s
Human trial stage
Phase 2–3
Musculoskeletal trials
0
About this library
Dossiers are published when sufficient primary-source evidence exists to compile a substantive, well-referenced summary. Each entry is reviewed periodically as new trial data becomes available. Evidence-level grading reflects the current highest-quality published evidence; it is not an endorsement of any therapeutic use.